Article
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
The New England journal of medicine - 14 Feb 2013
Ho Alan L, Grewal Ravinder K, Leboeuf Rebecca, Sherman Eric J, Pfister David G, Deandreis Desiree, Pentlow Keith S, Zanzonico Pat B, Haque Sofia, Gavane Somali, Ghossein Ronald A, Ricarte-Filho Julio C, Domínguez José M, Shen Ronglai, Tuttle R Michael, Larson Steve M, Fagin James A
Abstract excerpt
BACKGROUND: Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium-iodide symporter and uptake of iodine. Their effects in humans are not known. METHODS: We conducted a study to determine whether the MAPK kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.